Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.
It took 12 months for Teva to gain FTC approval to buy Allergan's U.S. generics business. Future mergers could face the same long scrutiny.
The pharmaceutical company announced that it will increase its patient assistance program in hopes of quelling a growing backlash over its drug pricing.
Despite Teva Pharmaceuticals (TEVA) losing two patents for its Copaxone drug, Leerink said generics won't challenge the company until 2018.